89bio to participate in upcoming investor conferences

San francisco, may 03, 2022 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that company's management will participate in the following upcoming investor conferences in may:

ETNB Ratings Summary

ETNB Quant Ranking